Published on 15/01/2025      Reading time : 2 minutes

 

Methotrexate Maintenance After Initiation
of Biological or Targeted Synthetic DMARDs
in Rheumatoid Arthritis: Results from the 2‑Year
Longitudinal Prospective Non‑interventional
STRATEGE2 Study

This page summarizes the 2‑year, longitudinal, prospective, non‑interventional STRATEGE2 study in routine care, focusing on whether to maintain methotrexate (MTX) when initiating a first biologic or targeted synthetic DMARD in rheumatoid arthritis (RA). We cite the peer‑reviewed article and authors below and link to the full text for verification.

 

stratege2

 

Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs in Rheumatoid Arthritis: Results from the 2-Year Longitudinal Prospective Non-interventional STRATEGE2 Study

 

 

Discover our publications in rhumatology: Rheumatology – RCTs